Compare · ABT vs LNDC
ABT vs LNDC
Side-by-side comparison of Abbott Laboratories (ABT) and Landec Corporation (LNDC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and LNDC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 652.3x LNDC ($308.1M).
- ABT has hit the wire 8 times in the past 4 weeks while LNDC has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 5 for LNDC).
- Company
- Abbott Laboratories
- Landec Corporation
- Price
- -
- -
- Market cap
- $200.95B
- $308.1M
- 1M return
- +6.30%
- -
- 1Y return
- -13.31%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 1996
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 5
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Landec Corporation
Landec Corporation, together with its subsidiaries, engages in the design, development, manufacture, and sale of differentiated health and wellness products for food and biomaterials markets. It operates through Curation Foods and Lifecore segments. The Curation Foods segment engages in processing, marketing, and selling of plant-based salads, and fresh-cut and whole processed vegetables primarily under the Eat Smart brand, O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products, as well as various private labels to retail grocery chains, club stores, and food service operators; and sells BreatheWay packaging products. The Lifecore segment manufactures pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products to treat various medical conditions and procedures. It also provides product development services, including technology transfer, material component changes, analytical method and formulation development, pilot and stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. It operates in the United States, Canada, Belgium, Switzerland, Czech Republic, Ireland, and internationally. The company was incorporated in 1986 and is headquartered in Santa Maria, California.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest LNDC
- Landec Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SCHEDULE 13G filed by Landec Corporation
- SEC Form SC 13G/A filed by Landec Corporation (Amendment)
- Schechter Joshua converted options into 9,554 shares, increasing direct ownership by 20% to 57,667 units (SEC Form 4)
- Calloway Nathaniel converted options into 3,981 shares, increasing direct ownership by 17% to 28,069 units (SEC Form 4)
- Obus Nelson converted options into 9,554 shares, increasing direct ownership by 12% to 88,687 units (SEC Form 4)
- Edwards Jeffrey L converted options into 9,554 shares, increasing direct ownership by 24% to 49,667 units (SEC Form 4)
- Diradoorian Raymond H converted options into 9,554 shares, increasing direct ownership by 31% to 39,978 units (SEC Form 4)
- Houde Lovas Katrina converted options into 9,554 shares, increasing direct ownership by 19% to 59,906 units (SEC Form 4)
- Barbarosh Craig A. converted options into 9,554 shares (SEC Form 4)